{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:41:58Z","timestamp":1780569718116,"version":"3.54.1"},"reference-count":8,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,14]]},"DOI":"10.1182\/blood.2021012300","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T01:56:20Z","timestamp":1634608580000},"page":"1287-1288","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Built to last: gene therapy for ADA SCID"],"prefix":"10.1182","volume":"138","author":[{"given":"Sung-Yun","family":"Pai","sequence":"first","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, National Institutes of Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2021101519135980900_B1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2020010260","article-title":"Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency (ADA SCID)","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood."},{"issue":"5577","key":"2021101519135980900_B2","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science."},{"issue":"97","key":"2021101519135980900_B3","first-page":"97ra80","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction [published correction appears in Sci Transl Med. 2013;5(168):168er1]","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med."},{"issue":"18","key":"2021101519135980900_B4","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood."},{"key":"2021101519135980900_B5","doi-asserted-by":"crossref","first-page":"648951","DOI":"10.3389\/fimmu.2021.648951","article-title":"Gene therapies for primary immune deficiencies","volume":"12","author":"Kohn","year":"2021","journal-title":"Front Immunol."},{"issue":"5","key":"2021101519135980900_B6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med."},{"issue":"5","key":"2021101519135980900_B7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J Clin Invest."},{"key":"2021101519135980900_B8","author":"Orchard Therapeutics"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/15\/1287\/1828669\/bloodbld2021012300c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/15\/1287\/1828669\/bloodbld2021012300c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T13:11:51Z","timestamp":1634649111000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/15\/1287\/477196\/Built-to-last-gene-therapy-for-ADA-SCID"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":8,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021012300","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]}}}